Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) Antibody | Affinity Biosciences LTD|亲科生物官网

产品:	磷酸化 PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) 抗体
货号:	AF3242
描述:	Rabbit polyclonal antibody to Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199)
应用:	WB IHC IF/ICC
反应:	Human, Mouse, Rat, Monkey
预测:	Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
分子量:	54kDa,84kDa; 84kD,54kD(Calculated).
蛋白号:	P27986 \| Q92569
RRID:	AB_2834668

浏览相似产品>>

阻断肽(封闭肽)是特异性结合目标抗体和阻断抗体结合的多肽。这些多肽包含抗体识别的抗原表位。与阻断肽结合的抗体不再与靶蛋白上的表位结合。例如，在免疫印迹(WB)和免疫组化(IHC)中，通过比较被阻断抗体和未阻断抗体的染色，可以看到哪种染色是特异性的。

规格	价格	库存
50ul	RMB¥ 1300	现货
100ul	RMB¥ 2400	现货
200ul	RMB¥ 3200	现货

货期: 当天发货

联系销售

实验方案

产品描述

来源:

Rabbit

应用:

WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:

Human,Mouse,Rat,Monkey

预测:

Zebrafish(100%), Bovine(86%), Horse(86%), Sheep(86%), Rabbit(100%), Dog(86%), Chicken(86%), Xenopus(86%)

克隆:

Polyclonal

特异性:

Phospho-PI3K p85(Tyr458)/p55(Tyr199) Antibody detects endogenous levels of PI3K p85/p55 only when phosphorylated at Tyr467(p85) or Tyr199(p55). The site Tyr467 was historically referenced as Tyr458.

RRID:

AB_2834668
引用格式: Affinity Biosciences Cat# AF3242, RRID:AB_2834668.

偶联:

Unconjugated.

纯化:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

保存:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

别名:

展开/折叠

GRB 1; GRB1; p85 alpha; p85; P85A_HUMAN; Phosphatidylinositol 3 kinase associated p 85 alpha; Phosphatidylinositol 3 kinase regulatory 1; Phosphatidylinositol 3 kinase regulatory subunit alpha; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 1 (p85 alpha); Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; Phosphatidylinositol 3-kinase regulatory subunit alpha; Phosphoinositide 3 kinase regulatory subunit 1 (alpha); Phosphoinositide 3 kinase regulatory subunit 1 (p85 alpha); Phosphoinositide 3 kinase regulatory subunit 1; Phosphoinositide 3 kinase regulatory subunit polypeptide 1 (p85 alpha); PI3 kinase p85 subunit alpha; PI3-kinase regulatory subunit alpha; PI3-kinase subunit p85-alpha; PI3K; PI3K regulatory subunit alpha; Pik3r1; PtdIns 3 kinase p85 alpha; PtdIns-3-kinase regulatory subunit alpha; PtdIns-3-kinase regulatory subunit p85-alpha; DKFZp686P05226; FLJ41892; OTTHUMP00000009783; OTTHUMP00000009786; p55; p55 gamma; P55G_HUMAN; p55PIK; Phosphatidylinositol 3 kinase regulatory subunit gamma; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 3; Phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55, gamma); Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma; Phosphatidylinositol 3-kinase regulatory subunit gamma; Phosphoinositide 3 kinase regulatory subunit 3 (gamma); Phosphoinositide 3 kinase regulatory subunit 3; Phosphoinositide 3 kinase regulatory subunit polypeptide 3; Phosphoinositide 3 kinase, regulatory subunit 3 (p55, gamma); Phosphoinositide 3 kinase, regulatory subunit, polypeptide 3 (p55, gamma); PI3 kinase p85 subunit gamma; PI3-kinase regulatory subunit gamma; PI3-kinase subunit p55-gamma; PI3K regulatory subunit gamma; Pik3r3; PtdIns 3 kinase p85 gamma; PtdIns-3-kinase regulatory subunit gamma; PtdIns-3-kinase regulatory subunit p55-gamma;

抗原和靶标

免疫原:

Uniprot:

P27986(P85A_HUMAN) >>Visit HPA database.

Q92569(P55G_HUMAN) >>Visit HPA database.

基因/基因ID:

PIK3R1(5295) | PIK3R3(8503)

表达:

P27986 P85A_HUMAN:

Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

Q92569 P55G_HUMAN:

Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle.

描述:

PIK3R1 is a regulatory subunit of phosphoinositide-3-kinase. Mediates binding to a subset of tyrosine-phosphorylated proteins through its SH2 domain. Acts as an adapter, mediating the association of the p110 catalytic unit of the alpha, beta and delta enzymes to the plasma membrane, where p110 phosphorylates inositol lipids. May play an additional role in the regulation of the actin cytoskeleton. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.

序列:

P27986 P85A_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTLQYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR

Q92569 P55G_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MYNTVWSMDRDDADWREVMMPYSTELIFYIEMDPPALPPKPPKPMTSAVPNGMKDSSVSLQDAEWYWGDISREEVNDKLRDMPDGTFLVRDASTKMQGDYTLTLRKGGNNKLIKIYHRDGKYGFSDPLTFNSVVELINHYHHESLAQYNPKLDVKLMYPVSRYQQDQLVKEDNIDAVGKKLQEYHSQYQEKSKEYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCHTQEQHSKEYIERFRREGNEKEIERIMMNYDKLKSRLGEIHDSKMRLEQDLKNQALDNREIDKKMNSIKPDLIQLRKIRDQHLVWLNHKGVRQKRLNVWLGIKNEDADENYFINEEDENLPHYDEKTWFVEDINRVQAEDLLYGKPDGAFLIRESSKKGCYACSVVADGEVKHCVIYSTARGYGFAEPYNLYSSLKELVLHYQQTSLVQHNDSLNVRLAYPVHAQMPSLCR

种属预测

种属预测:

score>80的预测可信度较高，可尝试用于WB检测。*预测模型主要基于免疫原序列比对，结果仅作参考，不作为质保凭据。

Species

Results

Score

Rabbit

100

Zebrafish

100

Horse

Bovine

Sheep

Dog

Xenopus

Chicken

Pig

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P27986/Q92569 作为底物

P27986
Q92569

Site	PTM Type	Enzyme	Source
	Ubiquitination		Uniprot
S2	Acetylation		Uniprot
Y12	Phosphorylation		Uniprot
S43	Phosphorylation		Uniprot
Y59	Phosphorylation		Uniprot
Y73	Phosphorylation		Uniprot
Y76	Phosphorylation		Uniprot
S83	Phosphorylation	P17612 (PRKACA)	Uniprot
T86	Phosphorylation		Uniprot
S147	Phosphorylation		Uniprot
T148	Phosphorylation		Uniprot
T152	Phosphorylation		Uniprot
S154	Phosphorylation		Uniprot
Y203	Phosphorylation	P07949 (RET)	Uniprot
S208	Phosphorylation		Uniprot
S265	Phosphorylation		Uniprot
S269	Phosphorylation		Uniprot
S279	Phosphorylation		Uniprot
K346	Ubiquitination		Uniprot
Y368	Phosphorylation	P06213 (INSR)	Uniprot
T369	Phosphorylation		Uniprot
K379	Ubiquitination		Uniprot
K419	Ubiquitination		Uniprot
Y426	Phosphorylation		Uniprot
K438	Ubiquitination		Uniprot
K448	Ubiquitination		Uniprot
Y452	Phosphorylation		Uniprot
T454	Phosphorylation		Uniprot
K459	Sumoylation		Uniprot
K459	Ubiquitination		Uniprot
Y463	Phosphorylation		Uniprot
Y467	Phosphorylation		Uniprot
Y470	Phosphorylation		Uniprot
T471	Phosphorylation		Uniprot
T490	Phosphorylation		Uniprot
Y504	Phosphorylation		Uniprot
K506	Ubiquitination		Uniprot
Y508	Phosphorylation	P09619 (PDGFRB)	Uniprot
K513	Ubiquitination		Uniprot
R514	Methylation		Uniprot
K519	Ubiquitination		Uniprot
R523	Methylation		Uniprot
Y528	Phosphorylation		Uniprot
K530	Acetylation		Uniprot
S541	Phosphorylation		Uniprot
Y556	Phosphorylation		Uniprot
K567	Ubiquitination		Uniprot
T576	Phosphorylation		Uniprot
Y580	Phosphorylation	P06213 (INSR)	Uniprot
T603	Phosphorylation		Uniprot
Y607	Phosphorylation	P06213 (INSR) , P12931 (SRC)	Uniprot
S608	Phosphorylation	P42336 (PIK3CA) , P68400 (CSNK2A1)	Uniprot
T623	Phosphorylation		Uniprot
S628	Phosphorylation		Uniprot
S629	Phosphorylation		Uniprot
K633	Ubiquitination		Uniprot
S652	Phosphorylation	Q15139 (PRKD1)	Uniprot
Y657	Phosphorylation		Uniprot
K674	Ubiquitination		Uniprot
Y679	Phosphorylation		Uniprot
Y688	Phosphorylation		Uniprot
S690	Phosphorylation		Uniprot

Site	PTM Type	Enzyme	Source
	Ubiquitination		Uniprot
K78	Ubiquitination		Uniprot
K106	Acetylation		Uniprot
K111	Ubiquitination		Uniprot
K114	Acetylation		Uniprot
K114	Ubiquitination		Uniprot
K155	Ubiquitination		Uniprot
Y163	Phosphorylation		Uniprot
K170	Ubiquitination		Uniprot
K180	Ubiquitination		Uniprot
Y184	Phosphorylation		Uniprot
S186	Phosphorylation		Uniprot
Y188	Phosphorylation		Uniprot
K191	Ubiquitination		Uniprot
Y195	Phosphorylation		Uniprot
Y199	Phosphorylation		Uniprot
Y202	Phosphorylation		Uniprot
T203	Phosphorylation		Uniprot
T222	Phosphorylation		Uniprot
K224	Ubiquitination		Uniprot
K238	Ubiquitination		Uniprot
Y260	Phosphorylation		Uniprot
S273	Phosphorylation		Uniprot
K274	Ubiquitination		Uniprot
K294	Ubiquitination		Uniprot
K299	Ubiquitination		Uniprot
K319	Ubiquitination		Uniprot
Y341	Phosphorylation	P06213 (INSR)	Uniprot
Y373	Phosphorylation		Uniprot
K375	Ubiquitination		Uniprot
K388	Ubiquitination		Uniprot
Y407	Phosphorylation		Uniprot

研究背景

P27986_P85A_HUMAN
Q92569_P55G_HUMAN

功能:

Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling. Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement.

翻译修饰:

Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.

Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear (By similarity). Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR.

组织特异性:

Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

亚基结构:

Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts (via SH2 domains) with CCDC88A/GIV (tyrosine-phosphorylated form); the interaction enables recruitment of PIK3R1 to the EGFR receptor, enhancing PI3K activity and cell migration. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with PIK3R2; the interaction is dissociated in an insulin-dependent manner (By similarity). Interacts with XBP1 isoform 2; the interaction is direct and induces translocation of XBP1 isoform 2 into the nucleus in a ER stress- and/or insulin-dependent but PI3K-independent manner. Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1 (By similarity). Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST. Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding). Interacts with FAM83B; activates the PI3K/AKT signaling cascade. Interacts with APPL1 and APPL2 (By similarity). Interacts with SRC.

(Microbial infection) Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV.

(Microbial infection) Interacts with HCV NS5A.

(Microbial infection) Interacts with herpes simplex virus 1 UL46; this interaction activates the PI3K/AKT pathway.

(Microbial infection) Interacts with herpes simplex virus 1 UL46 and varicella virus ORF12; this interaction activates the PI3K/AKT pathway.

蛋白家族:

The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.

Belongs to the PI3K p85 subunit family.

功能:

Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1.

组织特异性:

Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle.

亚基结构:

Heterodimer of a regulatory subunit PIK3R3 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts with AXL.

蛋白家族:

Belongs to the PI3K p85 subunit family.

研究领域

· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton. (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phosphatidylinositol signaling system.

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Glioma. (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer. (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway. (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway. (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway - multiple species. (View pathway)

· Organismal Systems > Development > Axon guidance. (View pathway)

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > Platelet activation. (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis. (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration. (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels. (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

· Organismal Systems > Excretory system > Aldosterone-regulated sodium reabsorption.

· Organismal Systems > Digestive system > Carbohydrate digestion and absorption.

文献引用

1). Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments. Nature Communications, 2022 (PubMed: 35918337) [IF=16.6]

2). MiR-146b-5p enriched bioinspired exosomes derived from fucoidan-directed induction mesenchymal stem cells protect chondrocytes in osteoarthritis by targeting TRAF6. Journal of nanobiotechnology, 2023 (PubMed: 38105181) [IF=10.2]

Application: WB Species: Rat Sample: chondrocytes

Fig. 7 Enriched miR-146b-5p in F-MSCs-Exo inhibits PI3K/AKT/mTOR pathway by targeting TRAF6. (A, B) Western blot analysis was performed to detect the impact of F-MSCs-Exo on TRAF6 and the PI3K/AKT/mTOR pathway in rat chondrocytes. (C, D) The expression of TRAF6 was quantitatively analyzed using immunofluorescence staining and ImageJ software (scale bar = 10 μm). (E, F) Direct visualization of chondrocytes treated with nc-inhibitor and miR-146b-5p-inhibitor was performed using Alcian blue staining and safranin staining. (G, H) Western blot analysis was conducted to examine the expressions of TRAF6 and the PI3K/AKT/mTOR pathway in chondrocytes after treatment with nc-inhibitor and miR-146b-5p-inhibitor. (ns, no significant difference; *p

3). Morinda officinalis oligosaccharides mitigate depression-like behaviors in hypertension rats by regulating Mfn2-mediated mitophagy. Journal of Neuroinflammation, 2023 (PubMed: 36765376) [IF=9.3]

Application: WB Species: Rat Sample:

Fig. 6 Mfn2 mediated inactivation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) involved in the pro-autophagic effect of Morinda officinalis oligosaccharides. A Mfn2 expression was determined by quantitative polymerase chain reaction (qPCR) and western blotting. B The PI3K/Akt/mTOR pathway-related protein levels were determined by western blotting. C Fluorescent localization of the autophagosome (yellow) and autolysosome (red) using the GFP-mRFP-LC3 probe. D Autophagy-related protein levels, including LC3 and p62, were determined by western blotting. Data are shown as the mean ± standard deviation of three independent experiments. *p

4). ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death & Disease, 2019 (PubMed: 31591377) [IF=9.0]

Application: WB Species: Sample: glioma cells

Fig. 5| ACT001 inhibits glioma cells through the PI3K/AKT signalling pathway.f The PI3K/AKT pathway was detected in glioma cells before (Con) and 24 h after PAI-039 treatment at the indicated concentrations.The results were obtained from three independent experiments, and each experiment was performed in triplicate. Data are represented as the mean ± standard error of the mean (*P < 0.05, **P < 0.01)

Application: IHC Species: mouse Sample: Tumour

Fig. 7| ACT001 enhances the antitumour effect of cisplatin in vivo. a Xenograft assays in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. b Tumour volume changes in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. c Body weight changes in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. d IHC analysis of the PI3K, p-PI3K, AKT and p-AKT levels. Compared with the control group, the staining of p-PI3K and p-AKT was lighter in the ACT001 treatment groups. In the ACT001 + cisplatin treatment group, the staining of p-PI3K and p-AKT was lighter than in the ACT001-treated group.

5). miRNA-92a-3p Regulates Osteoblast Differentiation in Patients with Concomitant Limb Fractures and Traumatic Brain Injury Through IBSP/PI3K-AKT Inhabitation. Molecular Therapy-Nucleic Acids, 2021 (PubMed: 33717654) [IF=8.8]

Application: WB Species: mouse Sample: MC3T3-E1 cells

Figure 5. |PI3K/AKT signaling is involved in IBSP-regulated osteoblast differentiation(A)Transfection of agomiRNA-92a-3p, antagomiRNA-92a-3p, agomiRNA-NC, antagomiRNA-NC, and Lipofectamine 3000 control (200 mm) in MC3T3-E1 cells for 48 h.Western blot detection of the expression of PI3K and AKT after transfection.

Application: WB Species: Mice Sample: MC3T3-E1 cells

Figure 5 PI3K/AKT signaling is involved in IBSP-regulated osteoblast differentiation (A) Transfection of agomiRNA-92a-3p, antagomiRNA-92a-3p, agomiRNA-NC, antagomiRNA-NC, and Lipofectamine 3000 control (200 μm) in MC3T3-E1 cells for 48 h. Western blot detection of the expression of PI3K and AKT after transfection. (B) Western blot detection of IBSP, p-PI3K, and p-AKT levels after transfection with siRNA-NC, siRNA-IBSP, and controls for 48 h. (C–G) Transfection with Lipofectamine 3000, siRNA-NC, siRNA-PI3K, or siRNA-AKT for 48 h. (C) Protein-expression levels of p-AKT, AKT, p-PI3K, and p-PI3K using western blotting. (D–G) qPCR analysis of Col1a1 (D), ALP (E), OCN (F), and Runx2 (G) expression in bone precursor cells. (H) Western blot analysis of Col1a1, ALP, OCN, and Runx2 levels 48 h after transfection. (I) Alizarin red staining of MC3T3-E1 cells 3 weeks after transfection. (J) ALP staining of MC3T3-E1 cells 2 weeks after transfection. n = 3; data are presented as mean ± SD (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; # no significance).

6). Eicosapentaenoic acid-mediated activation of PGAM2 regulates skeletal muscle growth and development via the PI3K/AKT pathway. International journal of biological macromolecules, 2024 (PubMed: 38641281) [IF=8.2]

Application: WB Species: Mouse Sample:

Fig. 9. EPA targets PGAM2 and activates the PI3K/AKT pathway. A. Heatmap of differentially expressed genes as determined via RNA-seq. B. KEGG pathway analysis of differentially expressed genes. C. The MuSC protein levels of the components of the PI3K/AKT pathway after EPA treatment and PGAM2 interference were measured by western blotting (n = 3). D. ELISA for the effect of EPA after PGAM2 knockdown (n = 3). E. Effect of EPA on the protein levels of components in the PI3K/AKT pathway after knockdown as analyzed by western blotting (n = 2). F–G. Effects of EPA and a PI3K/AKT pathway inhibitor (GDC-0941) on the protein levels of components of the PI3K/AKT pathway in MuSCs (F) and C2C12 cells (G) as determined by western blotting (n = 3). H. Immunofluorescence staining of MyHC to evaluate the differentiation of MuSCs and C2C12 cells. Results are mean ± SEM. ANOVA post-hoc analysis was performed using Fisher's least significant difference test.

7). Cathepsin S activity controls chronic stress-induced muscle atrophy and dysfunction in mice. Cellular and Molecular Life Sciences, 2023 (PubMed: 37589754) [IF=8.0]

Application: WB Species: Mouse Sample:

Fig. 4 CTSS deficiency ameliorated stress-related anabolic and catabolic molecular alterations. a–e: Representative immunoblotting images and quantitative data for CTSS, IGF-1, IRS-2, p-PI3K, p-Akt, p-mTOR, p-FoxO1α, MuRF-1, MAFbx1, PGC-1α, PPAR-γ, C-caspase-3, and Bcl-2 in GAS muscles at Day 14 after stress (n = 3). Data are mean ± SEM, and p-values were determined by a one-way ANOVA followed by Bonferroni post hoc tests (b–e). CW: CTSS+/+ control mice, CK: CTSS−/− control mice, SW: 14-day-stressed CTSS+/+ mice, SK: 14-day-stressed CTSS−/− mice. *p

8). Agrimoniin sensitizes pancreatic cancer to apoptosis through ROS-mediated energy metabolism dysfunction. Phytomedicine, 2022 (PubMed: 34785107) [IF=7.9]

9). Xanthotoxol suppresses non-small cell lung cancer progression and might improve patients' prognosis. PHYTOMEDICINE, 2022 (PubMed: 35932608) [IF=7.9]

10). Insulin promotes the bone formation capability of human dental pulp stem cells through attenuating the IIS/PI3K/AKT/mTOR pathway axis. Stem cell research & therapy, 2024 (PubMed: 39075596) [IF=7.5]

Application: WB Species: Human Sample: DPSCs

Fig. 5 LY294002 attenuates the responsiveness of 10− 6 M insulin to the IIS/PI3K/AKT/mTOR pathway axis in human DPSCs. A LY294002 attenuated the inhibiting effect of 10− 6 M insulin on the protein expressions of INSR, IGF1R, and IRS1 in DPSCs at day 7. B and C LY294002 attenuated the responsiveness of 10− 6 M insulin to the PI3K/AKT pathway in DPSCs at day 7. D LY294002 attenuated the promoting effect of 10− 6 M insulin on the protein expression of mTOR in DPSCs at day 7. Representative western blotting (left) and quantification analysis (right). Data are expressed as the mean ± SD of n = 3. Full-length blots/gels are presented in Supplementary Figs. 3–6. *P

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.

Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) Antibody - #AF3242

产品推荐

相关下载

MSDS

说明书

COA